全文获取类型
收费全文 | 36270篇 |
免费 | 2830篇 |
国内免费 | 62篇 |
专业分类
耳鼻咽喉 | 312篇 |
儿科学 | 1235篇 |
妇产科学 | 1081篇 |
基础医学 | 4883篇 |
口腔科学 | 509篇 |
临床医学 | 4625篇 |
内科学 | 6524篇 |
皮肤病学 | 606篇 |
神经病学 | 3867篇 |
特种医学 | 721篇 |
外国民族医学 | 4篇 |
外科学 | 3452篇 |
综合类 | 381篇 |
一般理论 | 69篇 |
预防医学 | 4855篇 |
眼科学 | 521篇 |
药学 | 2445篇 |
中国医学 | 24篇 |
肿瘤学 | 3048篇 |
出版年
2023年 | 289篇 |
2022年 | 385篇 |
2021年 | 1164篇 |
2020年 | 706篇 |
2019年 | 1076篇 |
2018年 | 1218篇 |
2017年 | 873篇 |
2016年 | 1017篇 |
2015年 | 1053篇 |
2014年 | 1386篇 |
2013年 | 1975篇 |
2012年 | 2856篇 |
2011年 | 3098篇 |
2010年 | 1627篇 |
2009年 | 1364篇 |
2008年 | 2518篇 |
2007年 | 2519篇 |
2006年 | 2328篇 |
2005年 | 2196篇 |
2004年 | 1959篇 |
2003年 | 1694篇 |
2002年 | 1706篇 |
2001年 | 325篇 |
2000年 | 316篇 |
1999年 | 297篇 |
1998年 | 355篇 |
1997年 | 279篇 |
1996年 | 215篇 |
1995年 | 203篇 |
1994年 | 167篇 |
1993年 | 153篇 |
1992年 | 168篇 |
1991年 | 148篇 |
1990年 | 132篇 |
1989年 | 131篇 |
1988年 | 114篇 |
1987年 | 105篇 |
1986年 | 108篇 |
1985年 | 90篇 |
1984年 | 72篇 |
1983年 | 80篇 |
1982年 | 62篇 |
1981年 | 47篇 |
1979年 | 47篇 |
1978年 | 42篇 |
1977年 | 39篇 |
1976年 | 33篇 |
1974年 | 41篇 |
1973年 | 42篇 |
1970年 | 31篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
991.
Dairaghi DJ Oyajobi BO Gupta A McCluskey B Miao S Powers JP Seitz LC Wang Y Zeng Y Zhang P Schall TJ Jaen JC 《Blood》2012,120(7):1449-1457
The chemokine CCL3/MIP-1α is a risk factor in the outcome of multiple myeloma (MM), particularly in the development of osteolytic bone disease. This chemokine, highly overexpressed by MM cells, can signal mainly through 2 receptors, CCR1 and CCR5, only 1 of which (CCR1) is responsive to CCL3 in human and mouse osteoclast precursors. CCR1 activation leads to the formation of osteolytic lesions and facilitates tumor growth. Here we show that formation of mature osteoclasts is blocked by the highly potent and selective CCR1 antagonist CCX721, an analog of the clinical compound CCX354. We also show that doses of CCX721 selected to completely inhibit CCR1 produce a profound decrease in tumor burden and osteolytic damage in the murine 5TGM1 model of MM bone disease. Similar effects were observed when the antagonist was used prophylactically or therapeutically, with comparable efficacy to that of zoledronic acid. 5TGM1 cells were shown to express minimal levels of CCR1 while secreting high levels of CCL3, suggesting that the therapeutic effects of CCX721 result from CCR1 inhibition on non-MM cells, most likely osteoclasts and osteoclast precursors. These results provide a strong rationale for further development of CCR1 antagonists for the treatment of MM and associated osteolytic bone disease. 相似文献
992.
Mérino D Khaw SL Glaser SP Anderson DJ Belmont LD Wong C Yue P Robati M Phipson B Fairlie WD Lee EF Campbell KJ Vandenberg CJ Cory S Roberts AW Ludlam MJ Huang DC Bouillet P 《Blood》2012,119(24):5807-5816
The BH3-mimetic ABT-737 and an orally bioavailable compound of the same class, navitoclax (ABT-263), have shown promising antitumor efficacy in preclinical and early clinical studies. Although both drugs avidly bind Bcl-2, Bcl-x(L), and Bcl-w in vitro, we find that Bcl-2 is the critical target in vivo, suggesting that patients with tumors overexpressing Bcl-2 will probably benefit. In human non-Hodgkin lymphomas, high expression of Bcl-2 but not Bcl-x(L) predicted sensitivity to ABT-263. Moreover, we show that increasing Bcl-2 sensitized normal and transformed lymphoid cells to ABT-737 by elevating proapoptotic Bim. In striking contrast, increasing Bcl-x(L) or Bcl-w conferred robust resistance to ABT-737, despite also increasing Bim. Cell-based protein redistribution assays unexpectedly revealed that ABT-737 disrupts Bcl-2/Bim complexes more readily than Bcl-x(L)/Bim or Bcl-w/Bim complexes. These results have profound implications for how BH3-mimetics induce apoptosis and how the use of these compounds can be optimized for treating lymphoid malignancies. 相似文献
993.
Wilkinson ST Vanpatten KA Fernandez DR Brunhoeber P Garsha KE Glinsmann-Gibson BJ Grogan TM Teruya-Feldstein J Rimsza LM 《Blood》2012,119(6):1459-1467
Loss of major histocompatibility complex class II (MHC II) expression is associated with poor patient outcome in diffuse large B-cell lymphoma (DLBCL). As MHC II molecules are lost with plasmacytic differentiation in normal cells, we asked whether MHC II loss in DLBCL is associated with an altered differentiation state. We used gene expression profiling, quantum dots, and immunohistochemistry to study the relationship between MHC II and plasma cell markers in DLBCL and plasmablastic lymphoma (PBL). Results demonstrate that MHC II(-) DLBCL immunophenotypically overlap with PBL and demonstrate an inverse correlation between MHC II and plasma cell markers MUM1, PRDM1/Blimp1, and XBP1s. In addition, MHC II expression is significantly higher in germinal center-DLBCL than activated B cell-DLBCL. A minor subset of cases with an unusual pattern of mislocalized punctate MHC II staining and intermediate levels of mRNA is also described. Finally, we show that PBL is negative for MHC II. The results imply a spectrum of MHC II expression that is more frequently diminished in tumors derived from B cells at the later stages of differentiation (with complete loss in PBL). Our observations provide a possible unifying concept that may contribute to the poor outcome reported in all MHC II(-) B-cell tumors. 相似文献
994.
995.
Ditting T Freisinger W Siegel K Fiedler C Small L Neuhuber W Heinlein S Reeh PW Schmieder RE Veelken R 《Hypertension》2012,59(2):467-476
Other than efferent sympathetic innervation, the kidney has peptidergic afferent fibers expressing TRPV1 receptors and releasing substance P. We tested the hypothesis that stimulation of afferent renal nerve activity with the TRPV1 agonist capsaicin inhibits efferent renal sympathetic nerve activity tonically by a neurokinin 1 receptor-dependant mechanism. Anesthetized Sprague-Dawley rats were instrumented as follows: (1) arterial and venous catheters for recording of blood pressure and heart rate and drug administration; (2) left-sided renal arterial catheter for selective intrarenal administration of the TRPV1 agonist capsaicin (3.3, 6.6, 10, 33*10(-7) m; 10 μL; after 15, 30, 45, and 60 minutes, respectively) to stimulate afferent renal nerve activity; (3) right-sided bipolar electrode for continuous renal sympathetic nerve recording; and (4) specialized renal pelvic and renal artery catheters to separate pelvic from intrarenal afferent activity. Before and after intrarenal capsaicin application, increasing intravenous doses of the neurokinin 1 receptor blocker RP67580 were given. Intrarenal capsaicin decreased integrated renal sympathetic activity from 65.4±13.0 mV*s (baseline) to 12.8±3.2 mV*s (minimum; P<0.01). This sustained renal sympathetic inhibition reached its minimum within 70 minutes and was not directly linked to the transient electric afferent response to be expected with intrarenal capsaicin. Suppressed renal sympathetic activity transiently but completely recovered after intravenous administration of the neurokinin 1 blocker (maximum: 120.3±19.4 mV*s; P<0.01). Intrarenal afferent activity could be unequivocally separated from pelvic afferent activity. For the first time we provide direct evidence that afferent intrarenal nerves provide a tonically acting sympathoinhibitory system, which seems to be rather mediated by neurokinin release acting via neurokinin 1 receptor pathways rather than by electric afferent effects on central sympathetic outflow. 相似文献
996.
Stow LR Richards J Cheng KY Lynch IJ Jeffers LA Greenlee MM Cain BD Wingo CS Gumz ML 《Hypertension》2012,59(6):1151-1156
The circadian clock protein period 1 (Per1) contributes to the regulation of expression of the α subunit of the renal epithelial sodium channel at the basal level and in response to the mineralocorticoid hormone aldosterone. The goals of the present study were to define the role of Per1 in the regulation of additional renal sodium handling genes in cortical collecting duct cells and to evaluate blood pressure (BP) in mice lacking functional Per1. To determine whether Per1 regulates additional genes important in renal sodium handling, a candidate gene approach was used. Immortalized collecting duct cells were transfected with a nontarget small interfering RNA or a Per1-specific small interfering RNA. Expression of the genes for α-epithelial sodium channel and Fxyd5, a positive regulator of Na, K-ATPase activity, decreased in response to Per1 knockdown. Conversely, mRNA expression of caveolin 1, Ube2e3, and ET-1, all negative effectors of epithelial sodium channel, was induced after Per1 knockdown. These results led us to evaluate BP in Per1 KO mice. Mice lacking Per1 exhibit significantly reduced BP and elevated renal ET-1 levels compared with wild-type animals. Given the established role of renal ET-1 in epithelial sodium channel inhibition and BP control, elevated renal ET-1 is one possible explanation for the lower BP observed in Per1 KO mice. These data support a role for the circadian clock protein Per1 in the coordinate regulation of genes involved in renal sodium reabsorption. Importantly, the lower BP observed in Per1 KO mice compared with wild-type mice suggests a role for Per1 in BP control as well. 相似文献
997.
998.
Blumberg SN Berger A Hwang L Pastar I Warren SM Chen W 《Diabetes research and clinical practice》2012,95(1):1-9
Metformin is a cornerstone in the treatment of type 2 diabetes. Although its mechanism of action is not well understood, there is new evidence about its possible role in cancer. A Pubmed search from 1990 to 2011 was done using the terms metformin, cancer, mechanism of action, diabetes treatment and prevention. We found more than one thousand articles and reviewed studies that had assessed the efficacy of metformin in treatment and prevention of type 2 diabetes and its mechanisms of actions, as well as articles on its antitumoral effects. We found that the United Kingdom Prospective Diabetes Study and the Diabetes Prevention Program have demonstrated the efficacy of metformin in terms of treatment and prevention of type 2 diabetes; metformin is safe, cost effective and remains the first line of diabetes therapy with diet and exercise. The mechanisms of action include a decrease of hepatic insulin resistance, change in bile acids metabolism, incretins release and decreased amyloid deposits. The AMP-activated protein kinase seems to be an important target for these effects. Epidemiological retrospective studies point out a possible association between metformin and decreased cancer risk, data supported by in vitro and animal studies. These data should trigger randomized controlled trials to prove or disprove this additional benefit of metformin. 相似文献
999.
1000.